P. emblica extract combined with doxorubicin or cisplatin resulted in synergistically enhanced growth inhibitory activity at different dose levels in A549 and HepG2 cell lines. The synergistic effects were also demonstrated when T. bellerica extract was combined with doxorubicin or cispaltin in HepG2 and A549 cells. The significance of this finding lies in the fact that doxorubicin and cisplatin are well-known cancer therapeutic agents, but cause high toxicity to normal tissues during cancer therapy